Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind active-controlled trial of YZJ-1139 tablets for adult insomnia
CTR20250036Phase 3Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fazamorexant in Insomnia, sponsored by Yangtze River Pharmaceutical Group. Started Jan 2025; status: completed.
02
Drugs
fazamorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on CTR20250036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250036.